PCV13对巴布亚新几内亚婴儿肺炎链球菌携带密度无效
本研究在巴布亚新几内亚比较接种与未接种PCV13婴儿的鼻咽部肺炎链球菌携带情况。结果显示,婴儿携带密度高且血清型多样,PCV13对总体、疫苗型及非疫苗型携带密度均无影响,对耐药基因流行率也无作用。
要点
- PCV13接种未降低婴儿肺炎链球菌携带密度。
- 疫苗型与非疫苗型携带率在接种与未接种组间相似。
- 婴儿携带密度高且血清型多样,非疫苗型占主导。
核心结论
- PCV13对巴布亚新几内亚婴儿肺炎链球菌携带密度无影响,对疫苗型血清型密度亦无效。
- 疫苗型携带率低、携带密度高及非疫苗型血清型丰富可能解释PCV13对携带无影响。
- 婴儿PCV规划的间接效应在巴布亚新几内亚可能有限,应考虑覆盖更广的替代疫苗。
研究设计与样本
- 研究采集接种PCV13婴儿(n=57)与年龄/季节匹配未接种婴儿(约1月龄n=53;4月龄n=57;9月龄n=52)在1、4、9月龄的鼻咽拭子。
- 采用qPCR和微阵列鉴定血清型特异性肺炎链球菌携带密度及抗菌素耐药基因。
主要发现
- 89%拭子检出肺炎链球菌,共检测到60种不同血清型和四种非荚膜变异体。
- 多血清型携带常见,占47%拭子。
- 4和9月龄时,接种与未接种婴儿的疫苗型携带率相似;4月龄时两组四分之三样本存在非疫苗型。
- 各年龄组中位肺炎链球菌携带密度高且相似(约7.0 log10基因组当量/mL)。
- PCV13对总体、疫苗型、非疫苗型携带密度及抗菌素耐药基因流行率均无影响。
临床怎么用
- 在巴布亚新几内亚等高携带密度地区,PCV13对携带密度无效,应评估覆盖更广的疫苗。
- 婴儿PCV规划的间接效应可能有限,需结合其他防控措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity. This study investigated PCV13 impact on serotype-specific pneumococcal carriage prevalence, density, and serotype diversity in PNG infants, who have some of the highest reported rates of pneumococcal carriage and disease in the world. METHODS: Nasopharyngeal swabs were collected at 1, 4 and 9 months of age from PCV13-vaccinated infants (n = 57) and age-/season-matched, unvaccinated infants (at approximately 1 month, n = 53; 4 months, n = 57; 9 months, n = 52). Serotype-specific pneumococcal carriage density and antimicrobial resistance genes were identified by qPCR and microarray. RESULTS: Pneumococci were present in 89% of swabs, with 60 different serotypes and four non-encapsulated variants detected. Multiple serotype carriage was common (47% of swabs). Vaccine type carriage prevalence was similar between PCV13-vaccinated and unvaccinated infants at 4 and 9 months of age. The prevalence of non-vaccine type carriage was also similar between cohorts, with non-vaccine types present in three-quarters of samples (from both vaccinated and unvaccinated infants) by 4 months of age. The median pneumococcal carriage density was high and similar at each age group (~7.0 log10genome equivalents/mL). PCV13 had no effect on overall pneumococcal carriage density, vaccine type density, non-vaccine type density, or the prevalence of antimicrobial resistance genes. CONCLUSION: PNG infants experience dense and diverse pneumococcal colonisation with concurrent serotypes from 1 month of age. PCV13 had no impact on pneumococcal carriage density, even for vaccine serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density and abundance of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in PNG infants. Indirect effects of the infant PCV programs are likely to be limited in PNG. Alternative vaccines with broader coverage should be considered.
引用
- Britton KJ, Pickering JL, Pomat WS, et al. Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants. Vaccine. 2021. PMID: 34384633. doi:10.1016/j.vaccine.2021.07.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。